• Prescribing Information
  • Patient Information
  • Patient Site
    • HomeEfficacySafety DataReal-World PatientsDosingSavings & Support
    Menu
    Phase III Study Primary Endpoint*
    Phase III Study Secondary Endpoints*
    Phase III Study: Other Endpoints*
    Infant Study: Exploratory Endpoint**

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    *Phase III pivotal studies and open-label safety extension study investigated in patients 2 years and older

    **Infant study investigated patients aged 3 to <24 months

    EUCRISA Efficacy

    Steroid-Free EUCRISA has proven efficacy in patients ≥ 2 years

    Quality of life (QoL) assessments: mean changes from baseline at Day 29 for EUCRISA and vehicle3

    Pooled results from 2 pivotal studies in patients 2 years and older3
    Baseline scores of both the DLQI and the CDLQI in the pivotal trials reflect a moderate effect of atopic dermatitis on patient lives.4-6 
    Composite scores are based on a scale of 0-304-6
    The higher the score, the greater the impairment of QoL.7
    MCID (or MID, as it is sometimes referred to) is the smallest difference in score that suggests there has actually been a meaningful change in studied patients’ quality of life since the previous measurement of his/her scores that would lead the patient or clinician to consider a change in management.8,9

    Dermatology Life Quality Index (DLQI): Patients ≥16 years of age3

    Children's Dermatology Life Quality Index (CDLQI): Patients 2-15 years of age3

    CDLQI is validated for use in children 4-16 years of age and can be completed with the help of the child's parent or guardian. The data presented includes patients 2-15 years of age. These results are consistent with the findings of a sub-group analysis in patients 4-15 years of age.6

    References
    1. ​​​​​​​EUCRISA® (crisaborole) Full Prescribing Information. April 2020.
    2. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e4.
    3. Data on File. Pfizer Inc., New York, NY.
    4. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AV. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol. 2005;125(4):659-664.
    5. Waters A, Sandhu D, Beattie P, Ezughah F, Lewis-Jones S. Severity stratification of Children's Dermatology Life Quality Index (CDLQI) scores. Br J Dermatol. 2010;163(suppl 1):121.
    6. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984-992.
    7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQl)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
    8. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AV. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33.
    9. Schünemann HJ, Guyatt GH. Commentary goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res. 2005;40(2):593-597.
    10. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase Ill randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64-70.
    11. Lewis-Jones MS, Finlay AV. The children's dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;19(3):210-216.
    12. Eichenfield LF, Tom WL, Berger TJ, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1)116-132.
    13. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
    14. Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020. 21:275-284.

    Proportion of patients with ISGA Clear or Almost Clear

    Find out more about the proportion of patients aged 2 years and older who achieved ISGA clear or almost clear at day 29 from the Phase III trial's secondary endpoint

    Learn more

    ** This is an optional area where footnotes can live.
    If babies could talk, what would they tell you?

    Hear JP with mild-to-moderate AD explain what EUCRISA means to him and other babies like him

    Not an actual patient

    Watch JP's story

    3 to <24 Month Study Data

    Learn more about 28-day, open-label, single-arm, safety study in 3 to <24 month old patients14

    See data

    ** This is an optional area where footnotes can live.

    Pivotal Trial Primary Efficacy Endpoint

    Find out more about the proportion of patients who achieved clear or almost clear at day 29 in the primary endpoint​​​​​​​

    Learn more

    ** This is an optional area where footnotes can live.
    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.